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Abstract 
Primary aldosteronism (PA) is the most common form of secondary hypertension 
and it is characterized by a Renin Angiotensin System (RAAS) independent 
overproduction of aldosterone by the adrenal glands. The clinical features of 
primary aldosteronism resemble the ones of an essential hypertensive patient (EH) 
but PA patients have a higher risk of cardiovascular events and a worse prognosis.  
Correctly diagnosed PA patients can benefit from specific treatments like the 
surgical removal of the aldosterone hyperproducing adrenal lesion or the 
administration of mineralocorticoid receptor antagonists (MRAs), depending on the 
features of the disease.  Diagnosis and subtyping are highly challenging tasks and a 
complex diagnostic work-up was developed to be used in clinical practice.  The 
identification of molecular markers of PA could provide new instruments that can 
help in the screening, diagnosis and characterization of this disease. 
In our study, we carried out different experimental strategies to improve the 
identification and characterization of PA by identifying specific molecular signatures, 
also taking advantages of urinary extracellular vesicles (UEV) analysis to identify 
prospect biomarkers in a non-invasive way. We propose a protocol for the 
investigation of mRNA content in UEV that provided information on the 
pathophysiological regulation of the sodium-chloride cotransporter transcript (NCC) 
in our proof-of-principle study. We analyzed the protein content of UEV through an 
untargeted MS-based approach that identified several biomarker candidates 
separating EH and PA patients, and we also detected significant differences in key 
proteins involved in water reabsorption pathway.  
Lastly, we carried out semi-targeted metabolomics analysis of serum samples from 
EH and PA patients, including a follow up of the metabolic changes in 7 aldosterone-
producing adenoma (APA) patients after surgical therapy in a 2-year time window. 
Through this approach, we discovered differences in purine, lipid and energy related 
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metabolites in PA and EH patients, as well as in PA subtypes APA and bilateral 
hyperaldosteronism (BAH). In our follow-up study we detected marked variations in 
the level of metabolites related to endothelium homeostasis and lipid mediators of 
inflammation. 
Through these strategies, we have identified several molecular markers that can 
improve the PA diagnostic work-up and we gained insight into the 
pathophysiological features of this disease, highlighting the usefulness of the -omics 
approaches in the investigation of complex diseases. 
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Sommario 
L’iperaldosteronismo primario (PA) è la più comune forma di ipertensione 
secondaria ed è caratterizzata da una produzione e secrezione di aldosterone nella 
corteccia surrenalica, in completa o parziale indipendenza dal sistema renina-
angiotensina. Le caratteristiche cliniche dell’iperaldosteronismo sono simili a quelle 
riscontrabili nei pazienti con ipertensione essenziale (EH) ma è noto che, rispetto ad 
essi, i pazienti con PA siano soggetti a un rischio maggiore di sviluppare eventi 
cardiovascolari. Una diagnosi corretta di PA permette a questi pazienti di poter 
ricevere un trattamento specifico, rappresentato dalla rimozione chirurgica della 
lesione surrenalica che causa la produzione incontrollata di aldosterone quando la 
malattia è monolaterale, o dalla somministrazione di inibitori del recettore dei 
mineralocorticoidi quando la malattia è bilaterale.  
La diagnosi e la sottotipizzazione di PA sono processi difficoltosi che hanno richiesto 
lo sviluppo di un complesso e articolato algoritmo diagnostico utilizzato in clinica. 
L’identificazione di marcatori molecolari di PA potrebbe fornire nuovi strumenti per 
migliorare lo screening, la diagnosi e la caratterizzazione di questa malattia. Nel 
nostro studio abbiamo adottato differenti strategie sperimentali con l’obiettivo di 
migliorare il riconoscimento e la caratterizzazione del PA tramite l’identificazione di 
molecole peculiari, sfruttando anche le caratteristiche delle vescicole extracellulari 
urinarie (UEV) come fonte di potenziali biomarker. 
In questo studio abbiamo proposto un protocollo per l’analisi del contenuto in 
mRNA delle UEV che abbiamo impiegato in un esperimento pilota per la 
quantificazione del trascritto del cotrasportatore sodio-cloro (NCC), una proteina 
chiave nel riassorbimento del sodio nel tubulo convoluto distale. Grazie a questo 
protocollo, abbiamo ottenuto informazioni sulla regolazione di NCC in condizioni 
patofisiologiche in pazienti PA ed EH. Abbiamo anche analizzato il contenuto di 
proteine nelle UEV tramite un approccio di tipo untargeted basato sulla 
spettrometria di massa, identificando diversi potenziali biomarker proteici capaci di 
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separare i pazienti EH dai PA ed evidenziando alcune differenze in proteine chiave 
nei meccanismi di riassorbimento dell’acqua a livello renale.  
Infine, abbiamo condotto uno studio di metabolomica sui campioni di siero di PA ed 
EH, includendo anche un follow-up di pazienti con aldosterone-producing-adenoma 
(APA), i cui campioni sono stati prelevati nell’arco di due anni. Con questo approccio 
abbiamo osservato che fra i gruppi PA ed EH esistono differenze metaboliche che 
coinvolgono il metabolismo di purine, lipidi e carboidrati, mentre nello studio follow-
up siamo riusciti a evidenziare delle notevoli variazioni in livelli di metaboliti 
coinvolti nell’omeostasi endoteliale e in lipidi mediatori dell’infiammazione. 
Grazie a queste strategie, abbiamo illustrato alcuni meccanismi di regolazione di 
trascritti, proteine e metaboliti nel PA e abbiamo identificato diversi potenziali 
marcatori molecolari che potrebbero contribuire a migliorare l’iter diagnostico. Il 
nostro studio evidenzia anche l’utilità degli strumenti di -omica per l’indagine di 
malattie complesse e l’identificazione di biomarker.  
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1. Introduction 
1.1 Primary aldosteronism 
Hypertension can pragmatically be defined as the level of blood pressure (BP) at 
which diagnosis and treatment are more beneficial than the associated risk without 
any intervention, and in clinic it is diagnosed when the levels of BP are above 
defined evidence-based cutoffs (1). Hypertension  is a known major risk factor for 
cardiovascular disease, it is a major cause of death and it represents one of the most 
challenging public health issues in developed and developing countries (2, 3). 
Worldwide prevalence of hypertension has been estimated to be around 1.13 
billion, with a global percentage ranging from 30 to 45% among adults (4, 5). 
Depending on its causes, hypertension can be classified as primary (essential) or 
secondary. While the causes of essential hypertension are not fully known being 
likely associated to interactions of several genetic, non-genetic and environmental 
risk factors, the secondary one is a consequence of clearly identifiable underlying 
causes. (5). 
Primary aldosteronism (PA) is currently considered as the most common form of 
secondary hypertension; it is characterized by an overproduction and secretion of 
the mineralocorticoid hormone aldosterone by the adrenal glands. This 
overproduction is partially or completely independent of the renin-angiotensin-
aldosterone system (RAAS) because it still occurs when renin is suppressed. High 
aldosterone causes an increased renal sodium and water retention with waste of 
potassium and ultimately leads to arterial hypertension and hypokalemia (6). As 
clinically important feature, the abnormal production of hormone may be due to 
bilateral hyperaldosteronism (BAH) or unilateral functioning adenoma. 
1.2 Genetics and molecular mechanisms of PA 
Several efforts have been made to understand the genetic basis of PA. In 
physiological conditions, aldosterone production responds to renin–angiotensin-
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aldosterone system (RAAS) regulation. The protease renin processes 
angiotensinogen to produce angiotensin I. Angiotensin converting enzyme (ACE) 
converts then angiotensin I into the active peptide angiotensin II. This peptide is 
then bounded by specific surface receptors on the zona glomerulosa cells in the 
outer layer of the adrenal cortex where, in association to extracellular K+, it triggers 
membrane depolarization. Change in membrane potential stimulates the voltage-
dependent L and T type Ca2+ channels and the increase in calcium influx stimulates 
the aldosterone synthase CYP11B2 (7).  
Choi and colleagues were the first to demonstrate that one of the genetic causes of 
the unilateral form of PA aldosterone producing adenoma (APA) was a somatic 
mutation on KCNJ5 gene, encoding for the inward-rectifier potassium channel Kir3.4 
(8). The mutations in KCNJ5 are located in the selectivity filter of this channel that 
becomes permeable to sodium ions, allowing them to contribute to membrane 
depolarization and consequent calcium entry. Their findings were then followed by 
the discovery of other mutations in several genes including the voltage-gated 
calcium channel Cav1.3 (CACNA1D), in Na+/K+ and Ca2+ ATPases (ATP1A1, ATP2B3) 
and beta-catenin (CTNNB1) (9-13). Despite some of the molecular mechanisms that 
characterize aldosterone over-production and secretion are now clear in APA, 
molecular bases of BAH, the bilateral form of PA, are still unknown (14). 
Molecular mechanisms of aldosterone regulation on blood pressure involve the 
activity of several proteins. Aldosterone is a lipophilic molecule and can cross 
plasmatic membrane binding the cytoplasmatic mineralocorticoid receptor (MR) 
(15, 16). Once activated, MR works as a transcription factor regulating many 
downstream targets that promote sodium and water reabsorption. A complex 
network of transporters and channels is involved in sodium, chloride and potassium 
homeostasis in the kidney. A model of a distal convoluted tubule cell, the district 
that is critical for aldosterone-mediated sodium reabsorption, is shown in Figure 1.  
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Figure 1: model of DCT cells. NCC and ENaC (1 and 2) are highlighted. 
The epithelial sodium channel (ENaC) is the main and most characterized target of 
aldosterone-MR activity. This channel is also named after its amiloride-sensitivity 
and is composed by three homologous subunits (α, β, γ). This heteromultimeric 
membrane protein acts as a rate limiting step in the control of blood pressure and is 
regulated by mineralocorticoid signaling (17, 18). The GPI-anchored serine protease 
prostasin is one of the key regulators of ENaC. This protease cut an inhibitory 
peptide from the ENaC γ subunit, leading to an increased probability of the open 
conformation of the channel (19, 20). Prostasin was found to be secreted in urine 
and is considered to be a marker of ENaC activity in vivo (21) and our laboratory 
demonstrated that urinary excretion of prostasin is increased for PA patients (22). 
Another key player in salt reabsorption tubule that is affected by aldosterone is the 
thiazide-sensitive sodium chloride cotransporter (NCC). This member of the SLC12 
family of electroneutral cation chloride cotransporter is encoded by the SLC12A3 
gene and is located in the apical plasma membrane of epithelial cells in the distal 
convoluted tubule (DCT). It has been shown that the abundance of NCC is 
modulated by aldosterone (23, 24) but several others hormonal and non-hormonal 
stimuli can contribute to regulate its activity (25). Together with ENaC, NCC is critical 
for regulating the arterial blood pressure and it has been found that NCC can be 
physically associated with the epithelial channel in the distal portion of the distal 
Lumen 
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convoluted tubule (DCT2), where the two proteins are co-expressed. This 
association is modulated by aldosterone and likely it has an impact on their salt 
reabsorption functionality (26).  
1.3 Diagnosis and therapy 
The clinical features of PA patient are largely similar to those observed in EH 
patients. This makes  the right diagnosis not only  a complex task but also a possible 
challenging issue for the National Health Systems in terms of cost/effects ratio 
considering the large prevalence of the primary hypertension In the general 
population (27). in addition, it is now acknowledged that PA patients are 
characterized by an increased risk in developing cardiovascular and renal events 
when compared to EH patients. In presence of a high-to-normal sodium intake, PA 
can convey several detrimental effects on the cardiovascular system, including an 
increased probability of atrial fibrillation and heart failure. It also induces tissue 
inflammation, myocardial remodeling and fibrosis and central sympathetic 
overactivation that can contribute to target organ damage in heart, blood vessels 
and kidney, and these effects are largely mediated by the interaction of aldosterone 
to the mineralocorticoid receptor (MR) (15, 28-37).  
Initially, PA was considered to be rare, but its prevalence has recently been re-
evaluated by several studies that reviewed the previous estimations of 2% among 
the hypertensive population to approximately 10%. The screening for PA is not 
systematically adopted in many Hypertension Centers but only when aldosterone is 
above center-defined thresholds or when the patient is hypokalemic. For these 
reasons, PA can be factually considered to be still underdiagnosed, especially for 
milder and normokalemic forms (27, 38-40).  
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The last guidelines for the diagnosis of PA (Figure 2) start from the calculation of 
aldosterone-to-renin ratio (ARR) as screening test for subject that are suspected of 
PA. In the laboratory practice, renin (measured as plasma activity or plasma 
concentration) and aldosterone are assessed using radio-immunometric assays, 
although tandem-MS methods and automated chemiluminescence-base methods 
that measure in parallel both renin and aldosterone have been proposed (41-43). 
One of the drawbacks of this screening test is that no validated protocol has been 
agreed upon yet, and ARR cutoffs vary between referring centers that use different 
assay protocols. (44). Since the aim of the ARR screening is detecting PA at high 
sensitivity minimizing the likelihood of missing true positive, this test is prone to 
Figure 2: Diagnostic algorithm of PA. Modified from Funder, 2016. 
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include false positives (28, 45). The suggested step after ARR screening is a 
confirmatory test (that works in fact as an exclusion test), aimed at demonstrating 
that the aldosterone secretion does not respond to RAAS regulation. The 
confirmatory tests include oral sodium loading test, saline infusion test, 
fludrocortisone suppression test or captopril challenge test. Performance of these 
confirmatory tests may vary from different clinical settings and no official gold 
standard or cutoff values have been definitively validated yet. Moreover, 
confirmatory tests are not always applicable to all patients, due to the possibility of 
complications such as hypertensive crisis or acute heart decompensation (28, 46, 
47). However, the importance of a confirmatory test is that it can spare invasive 
procedures for PA subtyping to patients resulted falsely positive for ARR screening. 
It is suggested that the confirmatory test can be avoided in cases of spontaneous 
hypokalemia, when plasma renin is below detection level and plasma aldosterone 
concentration is above 20 ng dL-1 (or 550 pmol L-1) (28).   Computer Tomography 
(CT) and adrenal vein sampling (AVS) are aimed at the subtyping of PA, a 
fundamental step for the choice of the appropriate treatment, i.e. surgical or not. 
The use of CT to detect adrenal lesions has several limitations as lesions with size < 
10mm may be omitted; actually, the large majority of adrenal functioning lesions 
(APAs) may be included in such range. In one study where the performance of CT 
was compared to AVS, it was found that the accuracy of the former was of 53%. In 
22% of the cases, unilateral patients would have been excluded from receiving 
adrenalectomy while in 25% of the cases bilateral patients might have had 
unnecessary surgery (28). AVS is a procedure that measures directly the amount of 
cortisol-corrected aldosterone in both the adrenal glands by vein catheterization 
and overcomes most of the limitations of currently used imaging techniques. 
Despite being expensive, heavily reliant on the operator’s skills and experience and 
inherently susceptible to complications like vein rupture (estimated in about 1% of 
the procedures), this technique remains a key component in the PA diagnostic work-
up (27, 48, 49). Alternative method have been explored, including the promising 
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11C-metamidate PET, but due to its technical requirements it cannot be considered 
a  suitable tool on large scale (50). The selection of the appropriate therapeutic 
treatment (surgical curable vs surgical uncurable PA) is crucial. In the first category, 
aldosterone producing adenomas (APA) account for about 30% of total PA cases, 
while bilateral hyperaldosteronism accounts for the remaining cases (14, 27).  
Overall, the current work-up for the diagnosis of PA is cumbersome, time-
consuming, relatively expensive, and requires specific technical skills or experience 
so that it cannot be easily applied routinely to the multitude of the hypertensive 
population. Nevertheless, considering the high prevalence of PA among 
hypertensive patients, the increased risk of PA subjects in developing cardiovascular 
events and the availability of specific treatments that can control (or cure) the 
disease, an effective diagnostic work-up is of paramount value. One of the most 
important challenges in PA research is to improve the sensitivity, specificity, cost 
and time effectiveness of the diagnostic work-up and replace the now necessary 
invasive procedures with viable alternatives.  
A promising way to improve the identification and characterization of PA is finding 
specific molecular signatures (biomarkers) in matrixes collected from patients in 
non-invasive ways (e.g. urine) or less-invasive ways (e.g. blood). 
1.4 Urine and urinary exosomes as source of biomarkers 
Exosomes are extracellular membrane-bound vesicles with a diameter ranging from 
30 to 120 nm and can be found in a wide variety of biological fluids, including blood 
and urine. They are selectively released from intracellular multivesicular bodies 
(MVB) of virtually any cell type (Figure 3) and they have a unique biogenesis and 
composition (51). Generation of vesicles, trafficking and cargo sorting in MVBs are 
strictly dependent on a group of proteins called Endosomal Sorting Complex 
Required for Transport (ESCRT) (52, 53). 
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Figure 3: Exosomes (3) and microvesicles (1) biogenesis and internalization. From Raposo et 
al., 2013. 
Exosomes differ from apoptotic bodies and other membrane bound-vesicles by size 
and by the presence of markers such as members of tetraspanins family (e.g. CD9, 
CD63, CD81), heat shock proteins (e.g. HSP70) or protein related to MVB biogenesis 
(e.g. ALIX, TSG101), although most of the components are shared also with 
extracellular vesicles, lysosomes, endosomes or alpha-granules and cannot be 
considered exosome-specific (54). 
Exosomes play a significant role in cell-to-cell communication and carry selected 
components of the parent cell, such as proteins, metabolites, receptors and nucleic 
acids, including miRNAs and mRNAs. They are also rich in lipids and lipid-related 
proteins and phospholipases (55). Their biological functions have been related to 
many pathophysiological processes including cancer, immune-mediated diseases 
and cardiovascular diseases, and their content reflects the condition of the parent 
cell, making them an ideal source for potential biomarkers. The possibility of 
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isolating exosomes from body fluids appears therefore attractive as  a potentially 
effective diagnostic tool (56, 57). 
Exosomes that are isolated from urine (UE) are secreted from all the cells lining all 
the segments of the nephron and can provide information on kidney functionality, 
ion transport and tissue homeostasis. Their isolation is absolutely non-invasive and, 
since their cargo is protected by a lipid bilayer and theoretically reflect the 
pathophysiological condition of the cell-of-origin, low-abundant proteins and RNA 
that are present can be good putative biomarker candidates. (58, 59). For this 
reasons, several studies have explored the possibility to use UE as source of 
biomarker useful for the diagnosis of several diseases including kidney injury (CKD, 
AKI), glomerular injury, kidney fibrosis, cancer, diabetes and infections (60-64). 
Exosomes have already proved to be valuable also for PA and hypertension 
research: some studies have shown that UE cargo of patients suffering of 
mineralocorticoid-dependent arterial hypertension are enriched in proteins and 
miRNA related to salt reabsorption activity and regulation (65-67). 
Over the last decade, the increasing interest in investigating this subcellular fraction 
has made available many isolation protocols that exploits different strategies for the 
isolation of exosomes. Each isolation protocol makes use of a different feature to 
separate exosomes from other similar vesicles, with the most common strategies 
exploiting the differences in size and density (size exclusion chromatography, 
differential ultracentrifugation, ultrafiltration, precipitation) or the presence of 
surface markers (immune-based precipitation). However, it has been reported that 
different methods may yield different results and the choice of the most appropriate 
isolation and characterization strategy  may depend on the type of target  (60, 61). 
Another challenging aspect of the experimental design is to find an appropriate 
normalization method to obtain a reliable quantification of the molecular content of 
exosomes (64, 68). The recent efforts in the standardization of definitions, isolation 
protocols and the creation of dedicated databases and tools for exosomes and 
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extracellular vesicles have considerably improved exosomes research, though many 
critical aspects still remain to be fully addressed. The exosomes research community 
is currently involved in an effort for reaching a consensus that will help in the 
translation from bench to bedside of exosomes as diagnostic and therapeutic tools 
(69-72).  
1.5 Metabolomics in the study of hypertension and primary aldosteronism 
Metabolic phenotyping is the study of low molecular weight molecules produced 
within a biologic system and represents a powerful tool for understanding disease 
complexity (73). Profiling of metabolites obtained with state-of-the-art mass 
spectrometry technologies and protocols can provide invaluable information on how 
a biological system responds to environmental conditions, changes in homeostasis 
and pathologies, as metabolites constitute the final product of the network of 
cellular activities. In hypertension research, metabolomics has already been 
successfully used as investigation tool both in human and animal models (74-76).  
In the last three years, the research on PA has started to use metabolomics in the 
effort to improve the identification and characterization of the disease and to better 
understand the underlying pathophysiology. Our laboratory has started investigated 
the urinary metabolic signature in primary aldosteronism patients by using a non-
invasive approach and we discovered that PA and hypertension are characterized by 
dysregulation in purine and sulfur metabolism, that BAH patients have a specific 
metabolic signature and that several metabolites were differentially regulated as 
function of sex variability (77). Arlt and colleagues have performed a profiling of 
steroid metabolome in patients with PA, discovering that glucocorticoid co-secretion 
is frequently found in primary aldosteronism and can contribute to associated 
metabolic risk (78). Murakami and colleagues have used the innovative approach of 
MSI (mass spectrometry imaging) to pinpoint metabolomics derangements in APA 
tissues, discovering that 18-oxocortisol was associated to a better clinical outcome 
after adrenalectomy (79). Together with state-of-the-art mass spectrometry 
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techniques, metabolomics could provide a significant amount of information 
relevant to the understanding of the underlying pathophysiology of PA but also 
useful to detect specific metabolic signatures that can be used as molecular markers 
in diagnosis and subtyping of the disease. 
 
  
20 
 
2. Description of the project and aims 
The main aim of this project is to improve the identification and characterization of 
PA by identifying specific nucleic acids, proteins and metabolites that can be 
considered markers of this pathology. The ultimate goal is to provide information 
that can be useful in clinical practice to separate PA patients in a population of 
hypertensive subjects. To achieve this, we have analyzed different clinical samples 
using both targeted and untargeted approaches. By quantifying molecular markers 
of PA and investigating their networks and pathways, our research strategies enable 
us also to pursue an important side aim: to gain insight on the pathophysiology of 
PA itself and acquire information that can be relevant in clinical practice for 
improving its subtyping and treatment. 
This project has been developed in three distinct parts: 
1. Analysis of the mRNA content of urinary extracellular vesicles (UEV), 
targeting specifically the NCC mRNA  
2. Analysis of the protein content of UEV of PA and EH patients (untargeted 
label-free MS quantification) 
3. Metabolomics of PA and EH patients (semi-targeted MS relative 
quantification) 
The first two parts are aimed at exploiting UEV as source of biomarkers for their 
capability of concentrating molecular information and for their non-invasive 
collection, while the last part is focused on serum metabolomics for the 
identification of specific metabolic markers of PA. 
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3. Materials and Methods 
3.1 Selection of patients 
We enrolled patients among hypertensives subjects referring to the Hypertension 
Unit of the Verona University Hospital (Verona, Italy). Patients were screened by 
mean of aldosterone-to-renin ratio (ARR). Screening samples were collected in the 
morning from fasting patients who remained out of bed for at least 2 h, after an 
adequate period of withdrawal of interfering drugs. As hypotensive treatment, only 
calcium-blockers or alpha-adrenergic blockers were allowed. PA diagnosis was 
confirmed in patients with elevated ARR value by intravenous salt loading test (IV-
SLT). An ARR value of 32 was previously defined as the cutoff for the screening (77). 
Samples from IV-SLT were collected after intravenous saline loading (2 l of 9% NaCl 
infused in 4 h), to confirm an autonomous aldosterone secretion. The test was 
considered positive when post-test aldosterone concentration was higher than 50 
pg ml-1 (138.7 pmol l-1). [28] In patients for whom plasma concentrations of 
aldosterone had an inadequate decrease after saline load, adrenal venous sampling 
was performed to define the disease subtype (BAH or monolateral APA) after a CT 
scan. Patients positive at both screening and confirmatory steps were diagnosed as 
PA and assigned to a disease subtype when possible (BAH or APA). Adrenal venous 
sampling (AVS)  was performed under unstimulated conditions, and was considered 
successful for a selectivity index (which  is  the  ratio  between  cortisol  in  the  
adrenal  vein and  cortisol  in  inferior vena cava) >2. For the diagnosis of 
monolateral or bilateral PA a lateralization index (calculated as the ratio  between 
cortisol-corrected aldosterone levels  in  one adrenal compare to the contralateral) 
of 2 was adopted. Patients negative for the screening test (i.e. with an ARR lower 
than the threshold) were defined as EH. In NCC mRNA analysis and Metabolomics 
experiments these patients are referred to as EH low-ARR. Patients positive for the 
screening test but with a negative confirmatory test (i.e. IV-SLT) are indicated as EH 
hi-ARR in Metabolomics experiments. 
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Blood and urine samples were collected at the recruitment, after confirmatory test 
(IV-SLT) and after therapy or surgery (e.g. after adrenalectomy and after mineral 
corticoid antagonist administration). In the case of MRA treatment, the samples 
were collected one month after the first administration. For patients who 
underwent adrenalectomy, samples were collected 3 months, one year and two 
years after. 
Routine laboratory test including measurement of biochemical and hormonal 
parameters were performed at the laboratory of the Clinical Chemistry Institute of 
the Verona University Hospital. Plasma aldosterone and renin levels were measured 
by using commercially available methods (Dia Sorin Diagnostics, Vercelli, Italy), as 
previously described (80).  
The study was performed according to the principles of the Declaration of Helsinki. 
Each patient provided written informed consent. The Institutional Review Board 
Ethical Committee approved the protocol. 
3.2 Biochemical and hormonal features of patients 
Overview of the features of patients involved in the three separate studies are 
shown in the relative results section. Statistics in these tables was calculated 
through t-test and non-parametric tests were used when data were not normally 
distributed, or variance was not homogenous. Chi-square test was used for 
proportions. 
3.3 Processing of clinical samples 
Urine 
Urine samples were collected and processed according to a previously reported 
protocol (21). Briefly, second morning urine samples were collected, chilled on ice 
and processed within one hour from collection. Urine pH was adjusted to 7.0 and a 
protease inhibitor cocktail was added (Complete Protease Inhibitor; Roche 
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Diagnostics, Basel, Switzerland) before centrifugation at 3500 rpm for 40 minutes at 
4°C. Supernatant was subsequently filtered using 0.22 µm filters (Millipore, Billerica, 
Massachussets, USA). Cell-free urine (CFU) was then stored in aliquots at -20°C. 
Urine processed as illustrated here were then used for further analysis (e.g. 
exosomes isolation). 
Blood 
Clinic routine blood draw was collected in three different Vacutainer (BD, Franklin 
Lakes, New Jersey) collection tubes (separation gel, citrate and EDTA tubes) and 
immediately centrifuged at 1500 g for 15 minutes. Plasma and serum were collected 
and stored in aliquots at -20 °C. Buffy coat was collected and stored separately at -
20°C. Remaining packed red blood cells were washed in saline solution and 
centrifugation step was repeated. Red blood cells were finally lysed with sterile 
water in 1:2 proportion and stored at -20 °C. 
3.4 TEM characterization of vesicles 
Exosomes pellet was thawed and resuspended in 100 µl of sterile PS and kept at 
+4°C. Aliquots of 6 µl of the suspension were absorbed for 1 minute on a ultra-thin 
carbon coated copper grid (CF200H-Cu-UL, Electon Microscopy Sciences) and excess 
of suspension was removed by gentle blotting. 
Suspension adsorbed to grid was placed on 1 drop of UranyLess solution (Electon 
Microscopy Sciences) for 1 second. Operation was repeated and the second drop 
was left in place 30 seconds. Grid was then dried by gentle blotting and air. Sample 
was then visualized on a a Morgagni 268D (FEI Philips) transmission electron 
microscope, setting the voltage to 80kV. 
A recent position paper on exosomes research suggest that the term “exosome” 
should describe only vesicles with a confirmed MVB origin and release. Where 
possible, in this thesis the term “urinary exosome” (UE) has been replaced by the 
24 
 
more generic term “urinary extracellular vesicles” (UEV) and the term “exosome” 
remained for referring to papers, databases and protocols that preceded this 
position paper (72). 
3.5 NCC mRNA analysis 
3.5.1 Isolation and characterization of urinary extracellular vesicles 
Urine samples were thawed and extensively vortexed to increase the exosomes 
yield(81). Aliquots (5 ml) were mixed with an equal volume of a commercially 
available exosomes extraction reagent (Total Exosome Isolation Reagent from urine; 
ThermoFisher Scientific, Waltham, Massachusetts, USA) and incubated 1 hour at RT. 
3.5.2 RNA extraction and analysis 
Urine samples and the corresponding volume of the reagent were transferred into 
polypropylene centrifuge tubes and centrifuged 1 hour at 10.000 g and 4°C. 
Supernatant was carefully removed and UEV RNA was extracted with commercial kit 
(PureLink RNA Micro kit; Invitrogen, Carlsbad, California, USA) following the 
manufacturer’s instructions. RNA was eluted in a final volume of 15 µl and stored at 
-80 °C. 
The cDNA synthesis was carried out using a commercial kit (iScript Advanced cDNA 
synthesis kit for RT-PCR; Biorad, Hercules, California, USA). To improve mRNA 
detection and measurement, a preamplification step was included (SsoAdvanced 
PreAmp Supermix; Biorad, Hercules, California, USA). Preamplification primer mix 
included the genes SLC12A3 and B2M. RealTime PCR was performed using SYBR 
green detection (SsoAdvanced Universal SYBR Green Supermix; Biorad, Hercules, 
California, USA) and all reactions were performed in 96-well plates in duplicate. All 
RealTime PCR runs included a negative control containing all the reaction reagents 
without cDNA. Specificity of the target was assessed by melt curve analysis. Intron-
spanning primers (Biorad, Hercules, California, USA) were used for target and 
housekeeping genes. NCC primers amplify all the three isoforms of the gene (82). 
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B2M gene use as normalizer was based on primer efficiency and absence of PCR 
product detection after no reverse-transcriptase control experiments. Housekeeping 
gene was detectable in all samples investigated. When the NCC transcript was 
undetectable, a reference value of 40 Ct was used. 
3.6 Proteomic analysis of urinary extracellular vesicles 
3.6.1 Vesicles and proteins extraction 
Ultracentrifugation protocol was adapted from Pisitkun et al. with the adjustments 
suggested by Livshits and colleagues (83, 84). Aliquots of urine (10 ml) were 
centrifuged at 17000 g for 15 minutes at 4°C to remove urinary sediment, including 
whole cells, large membrane fragments and other debris. Supernatant was then 
centrifuged at 50000 g for 120 minutes at 4°C to obtain a low-density membrane 
pellet. This pellet was resuspended either in 400 µl of ammonium bicarbonate 100 
mM (AMBIC) or RIPA buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 0.5% sodium 
deoxycholate, 1% NP-40, 0.1% SDS with 1mM NaF and Complete Roche protease 
inhibitor cocktail). 
3.6.2 Mass Spectrometry analysis 
Sample processing for MS analysis and data collection were conducted at the Mass 
Spectrometry unit of the University of Piemonte Orientale (Novara, Italy). These 
analyses were performed in the frame of a collaborative project.  
Proteins extracted from UEV were quantified using BCA assay (Pierce BCA protein 
assay kit; ThermoFisher Scientific). Samples were denaturated with TFE, reduced in 
DTT 200 mM and alkylated with IAM 200 mM before complete tryptic digestion with 
2 μg of Trypsin/Lys-C (Promega, Madison, WI, USA). Digested peptides were 
desalted on the Discovery® DSC-18 solid phase extraction (SPE) 96-well Plate (25 
mg/well) (Sigma-Aldrich Inc., St. Louis, MO, USA) and vacuum evaporated to be 
reconstituted with 20 μL of 0.05% formic acid in water. 
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For each sample, 4 µg of trypsin-digested proteins were analyzed with a micro-LC 
Eksigent Technologies (Eksigent Technologies, Dublin, CA, USA) system that included 
a micro LC200 Eksigent pump with flow module 5-50 µL, interfaced with a 5600+ 
TripleTOF system (Sciex, Concord, ON, Canada) equipped with DuoSpray Ion Source 
and CDS (Calibrant Delivery System). The stationary phase was a Halo C18 column 
(0.5 x 100 mm, 2.7 µm; Eksigent Technologies, Dublin, CA, USA). The mobile phase 
was a mixture of 0.1% (v/v) formic acid in water (A) and 0.1% (v/v) formic acid in 
acetonitrile (B), eluting at a flowrate of 15.0 µL min−1 at an increasing concentration 
of solvent B from 2% to 40% in 30 min. For identification purposes the samples were 
subjected to a data dependent acquisition (DDA): the mass spectrometer analysis 
was performed using a mass range of 100–1500 Da (TOF scan with an accumulation 
time of 0.25 s), followed by a MS/MS product ion scan from 200 to 1250 Da 
(accumulation time of 5.0 ms) with the abundance threshold set at 30 cps (35 
candidate ions can be monitored during every cycle).  
For the label-free quantification the samples were subjected to cyclic data 
independent analysis (DIA) of the mass spectra, using a 25-Da window: the mass 
spectrometer was operated such that a 50-ms survey scan (TOF-MS) was performed 
and subsequent MS/MS experiments were performed on all precursors. These 
MS/MS experiments were performed in a cyclic manner using an accumulation time 
of 40 ms per 25-Da swath (36 swaths in total) for a total cycle time of 1.5408 s. The 
ions were fragmented for each MS/MS experiment in the collision cell using the 
rolling collision energy. The MS data were acquired with Analyst TF 1.7 (Sciex, 
Concord, ON, Canada). Two DDA and three DIA acquisitions were performed. The 
DDA files were searched using Protein Pilot software v. 4.2 (Sciex, Concord, ON, 
Canada) and Mascot v. 2.4 (Matrix Science Inc., Boston, MA, USA). The data 
normalization was carried out through total peak area method. The UniProt Swiss-
Prot reviewed database containing human proteins was used and a target-decoy 
database search was performed. A minimum number of 2 peptides was used for the 
identification. False Discovery Rate was set at 1%. 
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3.7 Metabolomics 
3.7.1 Sample processing and metabolite extraction 
General metabolomics extraction: Serum samples were thawed on ice and vortexed. 
Aliquots of 20 ul of serum were mixed with 480 ul of ice-cold extraction buffer made 
of MeOH, ACN and H2O mixed in the proportion of 5:3:2. Samples were the n 
vortexed vigorously for 30 minutes at 4 C before being centrifuged for 10 minutes at 
maximum speed (the maximum speed of our benchtop centrifuge was 10,213 g). 
Aliquots of 100 ul of clear supernatant were transferred into labeled and cooled 
autosampler vials. As quality control, a pooled mixture of 10 ul aliquots of extracts 
was assembled. Blank was assembled from pure extraction buffer. 
Oxylipins metabolomic extraction: procedure was similar to the one described for 
general metabolomics with some changes. 20 ul of serum were mixed with 180 ul of 
pure ice-cold MeOH. Samples were briefly vortexed and kept at -20 C for 30 minutes 
before the centrifuge step. Clear supernatant was mixed in proportion 1:2 with 10 
mM ammonium acetate solution before transferring the extracts in autosampler 
vials. 
3.7.2 Ultra-High-Pressure Liquid Chromatography-Mass Spectrometry metabolomics 
Classic metabolomics was run on a 5 minutes gradient method. Column in use was a 
C18 (Kinetex® 1.7 µm C18 100 Å, LC Column 30 x 2.1 mm, Ea, Phenomenex, USA). 
(85) 
For positive mode, mobile phases were A: H2O + 0.1% FA; B: CAN + 0.1% FA. 
Negative mode run used A: 5% ACN, 95% H2O + 1 mM ammonium acetate and B: 
95% ACN, 5% H2O and 1 mM ammonium acetate. 
Chromatography conditions were as follow: flow rate 0.25 mL/min; solvent 
composition 95% A, 5% B from time zero until 3 min; column temperature 25 C; 
sample compartment temperature 7 C. 
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For positive or negative mode, the MS settings were: 70,000 (Q Exactive) or 60,000 
(Q Exactive HF), scan range 65-900 m/z, maximum injection time 200 ms, 2 
microscans, automatic gain control (AGC) 3 x 106 ions, ESI source voltage 4.0 kV, 
capillary temperature 320 oC, and sheath gas 45, auxiliary gas 25, and sweep gas 0 
(all nitrogen, measured in arbitrary units). 
For oxylipins analysis, analytes were separated on a C18 column (Acquity HSS T3, 2.1 
3 100 mm, 1.8 um, Waters). The mobile phase was composed of A: 
water/acetonitrile (75/25, vol/vol) with 5mM  ammonium acetate and B: 2-
propanol/acetonitrile/water (50/45/5, vol/vol/vol) with 5mM ammonium acetate. 
Chromatography method and conditions were as follow: column temperature 45 C; 
sample compartment 7 C. Solvent gradient: 0-1 min 25% B FR 0.3 mL/min; 1-2 min 
25-5-% B; 2-8 min 50-90% B; 8-10 min 90-99% B; 10-14 hold B at 99%; 14-14.1 99-
25B; 14.1-16.9 hold 25% B and FR 0.4 mL/min. 16.9-17 min hold 25% B and resume 
FR to 0.3 mL/min. (86) 
MS settings: 4.0 kV source voltage, 320 oC capillary temperature, and 45 sheath gas, 
15 aux gas, and 0 sweep gas (all nitrogen). Polarity was negative only.  
3.7.3 Statistical Analyses 
Multivariate analyses, including partial least square-discriminant analyses (PLS-DA) 
and hierarchical clustering analyses were performed with MetaboAnalyst 4.0.59. 
Other analyses and figures were prepared using R (v. 3.6.1). 
Samples extraction and analysis were conducted in the Metabolomics Lab of the 
University of Colorado, Denver under the supervision of Prof. D’Alessandro 
(Department of Biochemistry and Genetics). These analyses were performed in the 
frame of a collaborative project. 
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4. Results and Discussion 
4.1 NCC mRNA analysis in PA and EH patients 
In this study, we analyzed the UEV transcript level of NCC, key player in salt 
reabsorption pathway in the distal nephron, across PA and EH patients. For this 
study, we have enrolled 13 EH patients and 12 PA patients (8 APA and 4 BAH). Their 
biochemical and hormonal features are reported in table 1. PA and EH groups were 
significantly different for plasma renin, aldosterone, ARR and serum potassium, as 
expected. Of note, all patients were studied without medications interfering with 
ARR determination. 
Table 1: Biochemical and hormonal features of the patients enrolled in NCC mRNA study. 
Values are indicated as mean ± SD or median (CI) for non-normally distributed data. 
 
PA patients (12) EH patients (13) pval 
Gender (m/f) 12/0 7/6 < 0.05 
Age (ys) 51.8 ± 11.9 50.1 ± 12.2 NS 
BMI 28.2 (22.6, 35.2) 27.6 (24.6, 31.0) NS 
Renin 2.2 (1.2, 5.7) 8.3 (4.5, 15.3) < 0.01 
Aldosterone (pg ml-1)  286.5 ± 113.2  202.5 ± 68.2 < 0.05 
ARR 131.7 (45.1, 384.8) 22.9 (11.9, 43.7) < 0.01 
Serum K (mmol l-1)  3.5 ± 0.5 3.9 ± 0.3 < 0.05 
Creatinine (mg dl-1)  1.0 ± 0.1 0.9 ± 0.3 NS 
Glucose (mmol l-1)  5.0 (4.4, 5.7) 4.7 (4.4, 5.1) NS 
Cholesterol (mg dl-1) 176,4 ± 55.6  204.5 ± 43.8 NS 
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Triglycerides (mg dl-1) 84.2 (57.8, 124.3) 95.0 (68.1, 132.5) NS 
4.1.1 UEV TEM characterization 
Our isolated UEV were characterized by TEM (Figure 4). The average size of our 
vesicles was around 90 nm, compatible with the described size for exosomes. 
 
4.1.2 NCC mRNA analysis  
Urinary extracellular vesicles (UEV) were collected and analyzed for NCC mRNA 
content in 25 hypertensive subjects. After RNA extraction and cDNA synthesis a step 
of preamplification was introduced to improve the detection, as the quantity of 
exosomal mRNA was very low (around 20 pg/ul in most cases). UEV NCC mRNA 
relative abundance was expressed as dCt (calculated as Ct TARGET – Ct HOUSEKEEPING) 
reversed from positive to negative for a more immediate interpretation. Higher 
values of dCt correspond to a more abundant transcript, and vice-versa. 
Figure 4: TEM analysis of UEV obtained using the chemical precipitation. 
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Firstly, we assessed UEV NCC mRNA in patients at their enrollment. NCC mRNA 
levels’ distribution for PA and EH subject is indicated in Figure 5 (panel a). PA 
patients were also subdivided in APA and BAH subtypes (panel b). In both cases, 
transcript relative abundance between groups was not significantly different. 
Previous data have suggested that UEV of PA patients are characterized by an 
increased level of NCC protein (and its phosphorylated and active form: pNCC) when 
compared to exosomes from EH patients(66). According to this view, differences in 
protein abundance would be reflected by the level of the corresponding transcript. 
Thus, an intriguing hypothesis was that NCC mRNA could have been employed as a 
more stable and reliable marker of PA than the corresponding protein. Our results 
did not confirm such hypothesis and no statistically significant difference in NCC 
mRNA expression was observed in UEV from PA or EH patients (Fig 5a). Similarly, no 
difference was observed between the PA subtypes, i.e. patients with monolateral 
(APA) or bilateral (BAH) adrenal lesions (Fig. 5b).  
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Figure 5: (a) basal level of NCC mRNA in UEs of PA and EH patients. (b) basal NCC mRNA of 
PA patients separated for diagnosis subtype. 
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To investigate factors that can influence the NCC mRNA abundance, we measured 
the transcript in UEV samples from patients who resulted positive to the ARR 
screening and subsequently underwent confirmatory test (IV-SLT). In all EH patients 
and in 5 PA patients out of 6, the saline infusion led to a marked decrease of the 
level of NCC mRNA (Figure 6a). The PA patient characterized by an increase in NCC 
mRNA level was also an outlier for an extremely elevated ARR, due to the lowest 
level of plasma renin and the highest level of PAC measured among the subjects in 
our study (1 pg/ml and 532 pg/ml respectively). Unlike the creatinine values, we 
observed that B2M normalizer was not reduced after IV-SLT (Figure 6b and 6c).  
Creatinine is a spontaneous breakdown product of creatine, which is secreted by 
muscle cells at a constant rate throughout the day. This small molecule passes 
through the glomerulus filtration and is not reabsorbed in the renal tubule. This 
suggests that the NCC mRNA reduction is not an artifact due to changes in urine 
concentration after IV-SLT and that the accumulation of exosomes in urine could be 
not linearly compared to glomerular filtration capability and time. One of the 
assumptions of creatinine normalization for urinary vesicles is that the rate of 
release, uptake and clearance of vesicles in urine is constant. To present time, there 
are no data that support this claim. Measurement of urinary creatinine provides a 
readout of the filtration capability of the kidney and, for this reason, creatinine level 
has also been used in different studies for the normalization of urinary and 
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Figure 6: (a) Scatterplot of UEV NCC mRNA relative abundance before and after IV-SLT 
(pairwise T test, p<0.05). (b) Relative abundance of the housekeeping transcript B2M. (c) 
Creatinine concentration of the urine samples. 
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exosomal proteins. In UEV research, the quantification of known vesicles markers 
(e.g. CD9) represents a viable alternative to urinary creatinine normalization, though 
it has been reported that the two normalization strategies are not necessarily 
correlated and CD9 can also be affected  in immune response (62, 87). Taken 
together, these observations prompt to a careful evaluation of urinary creatinine as 
normalization factor for urinary exosomes, especially in experimental settings where 
spot urine samples are used and where short-term effects that can impact urine 
concentration and volume are analyzed. Nevertheless, in the context of exosomal 
transcripts evaluation, creatinine has shown several limitations dependent on the 
experimental settings (68, 88). 
a b 
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Figure 7: (a) MR and aldosterone regulate ENaC abundance and activities in genomic and 
non-genomic ways: MR+aldosterone complex can enhance the transcription of ENaC 
mRNA and SGK1 which inhibits the chromatin repression complex Dot1 and AF9. SGK1 can 
also block ubiquitination of ENaC and promote the channel activation by phosphorylation. 
MR acts also on PKD1 which contributes to increase he membrane trafficking of ENaC in 
multiple ways. Modified from Valinsky, 2019 and Quinn, 2013. (b) NCC mRNA level before 
and after administration of MRA. (c) Scatterplot of plasma renin and NCC mRNA level of 
patients after MRA treatment (Spearman R=-0.81; p=0.04). NCC mRNA variation is 
expressed as the log2 of the fold-change. (d) Trends of NCC mRNA after adrenalectomy 
performed on 4 APA patients (median and range are shown). 
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Spironolactone (SL) is a specific pharmacological inhibitor of the mineralocorticoid 
receptor (MR). MR is a key transcription factor in the salt reabsorption pathway that 
acts on different downstream targets, being ENaC one of the most relevant ones 
(Figure 7a). The binding of SL on the MR blocks its signaling activities, preventing an 
excessive sodium reabsorption and potassium exchange at the tubule level, so it is 
categorized as a potassium-sparing diuretic (89). 
SL it is the most acknowledged therapeutic choice for the control of blood pressure 
in PA and in resistant hypertension, and constitutes a first-line treatment for 
bilateral forms of PA. It is also indicated for treating unilateral forms of PA (including 
APA), when adrenalectomy is not feasible or desired, and prior to the surgery (28). 
Seven of the patients involved in this study were taking 25 mg/day of SL and urine 
samples were collected at baseline and after one month of treatment. UEV NCC 
mRNA level was measured and compared before and after MRA treatment (Figure 
7b). 
In 4 patients, the level of UEV NCC mRNA was found to be increased by the 
treatment. By analyzing biochemical and hormonal features of patients, we 
observed that plasma renin concentration was in correlation with NCC mRNA 
variation in abundance and such correlation was inversely proportional (Figure 7c). 
MR acts on different targets including ENaC and NCC. In particular, MR has been 
demonstrated to regulate ENaC abundance, transcription, trafficking and activity 
through a complex network of interactions (Figure 7a) (16, 90-98). On the other 
hand, it has been demonstrated that aldosterone stimulates the phosphorylation of 
NCC in a WNK-SPAK dependent manner but without affecting the total abundance 
or surface expression of the cotransporter (23). In a MR random-deletion 
experiment in mice it has been shown that, while alpha-ENaC was undetectable in 
MRko tubule cells, there was no difference in NCC abundance (18). Several other 
regulators can impact NCC functionality in an aldosterone independent way, 
including vasopressin and upstream players in the RAAS like angiotensin II (99-104). 
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The treatment with MRA has the ultimate effect of reducing sodium reabsorption 
and, consequently, blood volume. It is supposed that changes in the abundance of 
NCC mRNA are an indirect consequence of the reduced functionality of ENaC in the 
sodium reabsorption pathway and that such effects are not directly mediated by MR 
activity. In this view is interesting to consider that in never-treated hypertensive 
patients, ARR and low renin activity may predict the response to spironolactone 
(105). We are collecting more samples in order to confirm this hypothesis. 
We measured the NCC mRNA in UEV of 4 APA patients who underwent 
adrenalectomy, all achieving complete or partial clinical success according to the 
PASO criteria (106). We  observed the changes in the transcript abundance 3 months 
and one year after surgery (Figure 7d). After surgery, NCC mRNA increased in all 
patients, suggesting that the monolateral adrenalectomy and the related hormonal 
adjustment both deplete volume and stimulate the mRNA expression of NCC. 
Interestingly, after a longer period of follow-up (12 months), a clear trend was 
recorded toward pre-surgery levels, consistently with a complete reversal of the 
disease and full recovery of a normal blood volume, as generally observed in the 
clinical history of these patients.  
Taken together, our data indicate that the transcriptional regulation of NCC is closely 
regulated by Na-driven volume, with compensatory increases in case of 
hypovolemia following drug or surgical treatment or- in opposite direction- in case 
of Na loading. We also hypothesize different regulatory layers for NCC mRNA and 
protein in the distal convoluted tubule, and together with the short-term regulation 
that acts at post-translational level by modifying apical trafficking of NCC and its 
activation, we can hypothesize the existence of a long-term adaption  active  at 
transcriptional level. 
While there are no indications that NCC mRNA can be considered as a putative 
biomarker of PA, we showed that the analysis of mRNA content of UEV can provide 
information on the physiology and pathophysiology of the renal tubule, and with 
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this preliminary study we are proposing a new protocol for a non-invasive 
investigation of the transcriptional status in the kidney. 
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4.2 Proteomic analysis of urinary extracellular vesicles 
In this study we have analyze the proteomic content of UEV of PA and EH patients 
using an untargeted approach. Our isolated UEV were characterized by TEM and 
their average diameter was estimated to be around 80 nm, compatible to what is 
reported in literature for exosomes (Figure 8). Features of patients are reported in 
Table 2. 
 
 
 
 
Figure 8: representative picture of TEM characterization of UEV isolated with 
utltracentrifugation 
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Table 2: biochemical and hormonal features of patients enrolled in UEV proteomics study. 
Values are indicated as mean ± SD. 
 
PA patients – 24  
(13 APA, 11 BAH) 
EH patients  - 13 pval 
Gender (m/f) 15/9 8/4 NS 
Age (ys) 53.6 ±1.43 42.1 ± 4.8 <0.05 
BMI 27.9 ± 0.9 27.3 ± 0.8 NS 
Renin (pg/ml) 3.25 ± 0.8 18.7  ± 2.7 <0.01 
Aldosterone (pg/ml)  372.4 ± 31.3 174.4 ± 25.8 <0.01 
ARR 163.7 ± 47.3 11.33 ± 2.39 <0.01 
Serum K (mmol l-1)  3.29 ± 0.12 4.0 ± 0.10 <0.05 
Creatinine (mg dl-1)  0.88 ± 0.04 1.03 ± 0.26 <0.05 
Glucose (mmol l-1)  4.9 ± 0.17 4.9 ± 0.23 NS 
Cholesterol (mg dl-1) 192.3 ± 7.2 188.7 ± 11.1 NS 
Triglycerides (mg dl-1) 99.29 ± 13.2 91.67 ± 20.2 NS 
4.2.1 PA vs EH 
In the early diagnosis stages of PA, it is important to separate PA patients from EH 
subjects. To identify putative biomarkers, we compared the UEV proteome of 12 EH 
patients and 23 PA patients. In our proteomics analysis, we identified a total of 301 
proteins. T-test and fold-change analysis were used to identify prospects biomarker 
and subsequent network analysis was carried out to gain insight on the pathways 
involved in the definition of the pathology.  
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We have identified a total of 26 proteins differentially regulated between the two 
conditions, 13 proteins were up-regulated in PA (Figure 9 a, b). We compared our 
positive hits with proteins previously found in proteomics study on urinary 
exosomes in the database Vesiclepedia (VP) using FunRich 3, a free and standalone 
tool for functional enrichment (70). 8 of our differentially regulated proteins were 
not reported in VP.  
PA EH 
a b 
     c 
Figure 9:(a) Barplot of Log(fc) for proteins with pval < 0.05. Fold change cutoff was set to 1.5. 
Grey highlighted names indicate protein not previously reported in the Vesciclepedia 
database (http://microvesicles.org/ , filter: urinary exosomes experiments). Yellow 
highlighted names indicate proteins belonging to clusters identified with STRING 
(https://string-db.org/). (b) Volcano plot and distribution of pval and fold change of the 
positive hits. (c) Heatmap of the top 26 proteins resulting from t-test analysis. 
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In previous studies, we observed that there are significant sex-dependent 
differences in proteins and metabolites in urine (77, 107). Thus, we verified through 
t-test if the distribution of regulated proteins was influenced by sex. No significant 
differences were found analyzing the distribution of proteins in all the patients. 
However, analyzing the distribution within the diagnosis groups (PA and EH) we 
found significant differences for AQP1, YIPF3, AMPN in PA and B3GN8 in EH.  
To assess the performance of the putative biomarkers, we performed Receiver-
operating characteristic analysis (ROC) on the significant proteins. Setting the 
threshold of the area-under-curve (AUC) to 0.7, we identified 9 proteins increased in 
EH patients and 2 in PA patients as biomarker candidates (Figure 10 and Table 3).  
Due to the significant sex-dependent difference in the distribution of AQP1 in PA 
patients, we calculated ROC curve separately for men and women. AUC remained 
unchanged (Female AUC= 0.81; Male AUC=0.82) but the lower limit of CI dropped to 
0.42 for women (F CI=0.42, 1; M CI=0.61, 1). 
Figure 10: ROC curves of some of the candidate biomarkers. 
Table 3: AUC and CI values for selected proteins 
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Interestingly, the best performing protein GGT3 is a putative glutathione hydrolase, 
considered to be a non-functional product of a pseudogene (108). According to the 
database Genecards (www.genecards.org), kidney and thyroid tissues are the ones 
with the highest abundance of GGT3 mRNA. The role of this protein in these two 
organs is unknown. 
To identify pathway involved in the different regulations of UEV proteins, we carried 
out network analysis using Gene Ontology and the database STRING. In PA patients, 
Gene Ontology reported an enrichment for proteins involved in positive regulation 
of immune response and receptor-mediated endocytosis. In EH patients, proteins 
were found to be involved in renal water transport and cell activation involved in 
immune response.  
Figure 11: Boxplots and relative position in the nephron of AQP1, AQP2 and the target o. 
Adapted from Kortenoeven, 2014 
42 
 
AQP1 and AQP2 proteins, belonging to the renal water transport class, were found 
to be up-regulated in subjects of the EH group (Figure 11). Aquaporins are a family 
of transmembrane proteins that form pores in the membrane facilitating the 
transport of water using osmolarity as the driving force. Among the 13 identified 
aquaporins (AQP0-12), eight have been found in renal epithelial cells (AQP1-4, 6-8, 
11) and they are critical for the maintenance of the body water balance (109). 
AQP1 is localized in the apical and basolateral membrane of the epithelial cell in the 
proximal tubule, where a large part of the water filtered by the glomeruli (around 
65%) is reabsorbed through an isosmotic mechanism. AQP1 is stimulated by ANGII, 
that effects directly the expression of AQP1 mRNA (110). Thus, the increased 
expression of AQP1 (5.5-fold in EH over PA) may be a consequence of the status of 
the RAAS in PA patients, where plasma aldosterone is high and renin is suppressed.  
AQP2 is located in the apical plasma membrane in the collecting duct (CD) and it is 
the primary target for AVP regulation of CD permeability through trafficking of 
AQP2-loaded vesicles to the apical region or through an increase in AQP2 mRNA 
expression (111). By measuring the plasma concentration of copeptin (C-terminal 
portion of provasopressin) in PA and EH, it has been shown that cleavage of 
provasopressin was higher in PA patients, suggesting a higher and chronic activation 
of AVP signaling (112). Moreover, in an experiment aimed at the identification of 
aldosterone effects on AQP2, it has been demonstrated that, even though 
aldosterone causes a short-term decrease of AQP2 mRNA in mpkCCDC14 cells, it 
increases long-term (48 h) protein turnover and reduces the channel degradation in 
the lysosome, despite a persisting low level of AQP2 mRNA transcription (113). This 
is in contrasts with our observed 2.6-fold increase of AQP2 protein in UEV of EH 
patients. However it is possible to hypothesize that a longer and chronic exposure to 
high plasmatic aldosterone could negatively affect the abundance of AQP2 by acting 
on the abundance of mRNA or by altering the trafficking of intracellular vesicles and 
apical localization (114). 
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Notably, the level of AQP1 and AQP2 protein in exosomes correlates (with some 
exceptions) with their renal protein level, and it has been observed that the urinary 
fraction of AQP2 is mainly located in exosomes with preserved transport activity 
(115, 116). This protein (AQP2), in fact, it is commonly utilized as a marker of 
exosomal origin for urinary vesicles characterization. 
To identify protein-protein interactions and functional networks, we queried the 
database STRING (https://string-db.org/) with all the significant proteins together or 
separated for experimental groups. Two nodes differentially regulated were 
identified and the GO analysis for biological process reported an involvement of the 
“secretion pathways”, while the most significant GO term for cellular component 
was extracellular exosome (Figure 12). Proteins up-regulated in PA patients were 
found to be involved in regulated exocytosis and, more specifically, they were 
classified under alpha granule of platelets according to Reactome 
Figure 12: STRING analysis of regulated proteins. Text mining interactions were excluded. 
Nodes-relative boxplots are shown. CD63 resulted to be significantly higher in EH patients. No 
significant difference was found for CD9. 
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(https://reactome.org) classification. Alpha-granules are the most abundant 
secretory granules in platelets. Their content includes several growth factors and 
they are involved in many different functions, including wound healing and 
angiogenesis. Their size ranges from 200 to 500 nm and their maturation and 
release is strictly dependent on mature MVB, where also exosomes are assembled 
and sorted. Both alpha-granules and exosomes carry several surface markers in 
common, including CD9 and CD63 (117). Despite the number of common features, 
the alpha-granules are indeed characterized by a larger size when compared to 
exosomes. The TEM size assessment of the vesicles we isolated revealed an average 
size around 80 nm and the same proteins identified in the alpha-granules are listed 
in several exosomes experiments on the database Vesiclepedia, including 
experiments where exosomes were extracted from cell culture (FGG in VP ID and 
cell line: 348 (LIM1836) ; 591 (HT-29); 401 (THP-1); 738 (JEG-3) or urine (VP ID: 63; 
179; 382; 508; 498). These observations suggest the possibility that the proteins 
included in the up-regulated node in PA (e.g. gamma fibrinogen or the acute-phase 
glycoprotein ORM1) are not exclusive of alpha-granules but can be also carried by 
other smaller vesicles originated in the MVB, as the exosomes. The role of these 
proteins in the kidney is not yet understood and needs to be investigated. 
All the proteins found to be up-regulated in EH patients in the STRING node analysis 
showed association to exosomes biogenesis. Interestingly, one of the up-regulated 
proteins was CD63, a member of the tetraspanins family, commonly used as marker 
of exosomes and extracellular vesicles (albeit not exclusive of this subcellular 
fraction) and quantified for an indirect readout of the abundance of exosomes in a 
sample (64, 69, 87, 118). CD63 was found in association with LAMP2 (lysosomal 
associated membrane protein-2), glycoprotein frequently found in exosomes and 
late endosomes and significant correlations were found with other proteins up-
regulated in EH and involved in exosomes biogenesis (SDCB1) and members of the 
ESCRTIII complex (IST1) (CD63-SDCB1: R=0.72, p=8.1e-07; CD63-IST1: R= 0.45, 
p=0.005). 
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Extracellular vesicles and exosomes are populations characterized by a high level of 
heterogeneity and it has been demonstrated that differences in the markers 
exposed on the surface of exosomes can reflect differences in their cargo (119). As a 
relevant example of this, it has been found that the PA marker NCC is associated 
with CD9+ but not CD63+ urinary vesicles.(87). While the CD63+ fraction of UEV is 
more abundant in EH patients, we detected no significant differences in the 
abundance of CD9 marker (Figure 12).  
Taken together, our results indicate a strong variability in the composition of 
vesicles isolated from the urine of PA and EH patients. It is possible to hypothesize 
that this may depend on a different pathophysiological condition of the releasing 
tissue or a different tissue-of-origin of the vesicles. In addition, we found that in our 
settings CD63 and CD9 UEV markers do not correlate and their separate evaluation 
for normalization purposes may introduce biases when vesicle populations are 
enriched in different surface markers. For proteomics investigations on UEV, we 
hypothesize that normalization strategies independent of the vesicle composition 
(i.e. protein quantification or NTA count) could provide more reliable results. 
AQP1 and 2 values were found to be different between EH and PA patients and it 
has been shown that their level in urinary vesicles mirrors the level and functionality 
in the tissue. We can speculate that the reduced water absorption activity of AQP1 
and 2 in PA patients is a sort of long-term response to the expanded-volume 
hypertension. 
A subset of proteins significantly altered between the two groups have been already 
proposed as urinary biomarkers in other settings or have been observed to be 
altered under specific conditions (table 4).  
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Table 4: details on the significant protein hits in PA vs EH comparison, including literature 
references when used as urinary biomarkers in other settings. 
Protein Name Description Up-reg 
in 
Previously proposed as urinary 
biomarker? 
REF 
TPM4 Tropomyosin 
alpha-4 chain 
Actin filament 
binding, Calcium 
ion binding 
PA Up-regulated in TAL of Henle's loop cells 
under osmotic stress 
(120) 
A1AG1 Orosomucoid 
1 
acute-phase 
response 
PA Proposed as urinary marker of chronic 
heart failure, bladder cancer and active 
lupus nephritis in children. Is protective 
against renal ischemia-reperfusion injury 
(anti-inflammatory effect); Has been 
observed to ameliorate nephrotic 
syndrome in a mouse model. 
(121-
125) 
ZA2G Zinc-alpha-2-
glycoprotein 
transmembrane 
transporter 
PA Proposed as prognostic marker in prostate 
cancer.  Exerts Antifibrotic Effects in 
Kidney 
(126, 
127) 
SH3L3 SH3 Domain 
Binding 
Glutamate 
Rich Protein 
Like 3 
electron transfer 
activity; cell 
redox 
homeostasis 
PA Proposed as potential prognostic marker 
for urothelial carcinoma (binds EGFR) 
(128) 
A2GL Leucine-rich 
alpha-2-
glycoprotein 
TGFb binding; 
regulation of 
endothelial cells 
proliferation 
PA Increased in severe IgA nephropathy (129) 
DERM Dermatoponti
n 
cell adhesion PA - 
 
SCLT1 Sodium 
channel and 
clathrin linker 
1 
chlatrin binding PA Interacts with the voltage-gated Na 
channel Na(v)1.8 (SCN10A) and chlatrin. 
SCN10A is expressed also at kidney level. 
(130, 
131) 
IGKC Immunoglobu
lin Kappa 
Constant 
antigen binding, 
ig receptor 
binding 
PA Increased in urine of lung adenocarcinoma 
patients 
(132) 
FIBG Fibrinogen 
gamma chain 
blood 
coagulation, cell 
adhesion 
molecule inding, 
positive regulator 
PA Proposed as early diagnostic biomarker for 
AKI 
(133) 
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of exocitosis 
ZN736 Zinc Finger 
Protein 736 
nucleic acid 
binding 
PA - 
 
KV230 Immunoglobu
lin kappa 
variable 2-30 
antigen binding PA - 
 
KV320 Immunoglobu
lin kappa 
variable 3-20 
antigen binding PA - 
 
HEMO Hemopexin heme transporter 
activity, cellular 
ion homeostasis 
PA Proposed for diagnosis of chronic 
predisposition to AKI, urinary exosomal 
biomarker of acute T-cell mediated 
rejection in kidney transplant 
(134, 
135) 
IST1 IST1 homolog cadherin binding, 
MVB assembly 
EH - 
 
LAMP2 Lysosome-
associated 
membrane 
glycoprotein 
2 
enzyme binding, 
lysosomal protein 
cataboli process 
EH Increased in Cholangiocarcinoma patients (136) 
P3IP1 Phosphoinosit
ide-3-kinase-
interacting 
protein 1 
negative 
regulation of PI3K 
activity 
EH - 
 
AMPN Aminopeptida
se N 
aminopeptidase 
activity (ANGIII, 
IV are targets) 
EH Activity of aminopeptidases has been 
proposed as biomarker for bladder cancer.  
(137) 
A2ML1 Alpha-2-
macroglobuli
n-like protein 
1 
peptidase 
inhibitor activity 
EH Proposed as diagnostic and prognostic 
marker for necrotizing enterocholitis in 
infants 
(138) 
AQP2 Aquaporin-2 water transport EH Proposed as diagnostic biomarker of 
diabetic nephropathy 
(139) 
SDCB1 Syntenin-1 cytoskeletal 
adaptor activity 
(with PDCD6IP 
regulates 
exosome 
EH - 
 
48 
 
biogenesis) 
CD63 CD63 antigen cell-matrix 
adhesion 
EH - 
 
YIPF3 Protein YIPF3 cell 
differentiation 
EH - 
 
B3GN8 UDP-
GlcNAc:betaG
al beta-1,3-N-
acetylglucosa
minyltransfer
ase 8 
acetylglucosamin
yltransferase 
activity, protein 
glycosylation 
EH - 
 
TGM7 Protein-
glutamine 
gamma-
glutamyltrans
ferase Z 
protein-
glutamine 
gamma-
glutamyltransfera
se activity, 
peptide 
crosslinking 
EH - 
 
GGT3 Putative 
glutathione 
hydrolase 3 
proenzyme 
Pseudogene. 
Transcript is 
abundant in the 
kidney 
EH - (108) 
AQP1 Aquaporin-1 water transport EH AQP1-containing exosomes were 
proposed as biomarker of dialysis 
efficiency. AQP1 in urine has been 
proposed as screening marker for renal 
cell carcinoma 
(140) 
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4.2.2 APA vs BAH 
We performed a similar analysis to identify proteins that can separate the two main 
PA subgroups and help in the characterization of the disease. We compare the UEV 
proteome of 13 APA patients against 11 BAH patients. In this comparison we found a 
total of 25 differentially regulated proteins, 6 of which were not reported in VP 
database (as shown in Figure 13 a). Nine proteins were up-regulated in APA while 16 
were up-regulated in BAH patients (Figure 13).  
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Figure 13: (a) Barplot of Log(fc) for proteins with pval < 0.05 and FC cutoff of 1.5. Grey 
highlighted names indicate protein not previously reported in the Vesciclepedia database. 
(b) Volcano plot and distribution of pval and fold change of the positive hits. (c) Heatmap of 
the top 25 proteins resulting from t-test analysis. 
a b 
c 
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ROC curve analysis setting AUC threshold to 0.7 and lower limit of CI to >0.5 gave 8 
prospect biomarkers, all up-regulated in APA (Table 5 and Figure 14). Among the up-
regulated proteins in BAH patients we found CD63, AQP1 and AQP2 that were 
suggested as candidate biomarkers for differentiating PA vs EH patients in the 
previous comparison, even though none of them were above the threshold we set 
for AUC and CI in the shortlisting of the best candidates. 
As we showed that sex variable may affect the distribution of proteins, we 
performed Mann-Whitney test between the two PA subtypes. With the exception of 
CAH2, the proteins listed in the table 2 resulted all significantly different for the 
variable sex. This is probably due to the uneven distribution of the variable sex in 
our sample set. To improve the reliability of the selection of prospect biomarkers, 
we performed sex-separated ROC analysis. H4, LYSC, CAH2 and M1A1 maintained an 
AUC > 0.8 in all cases and a CI lower limit >0.5.  
One of the best performing protein from the ROC analysis resulted to be histone H4. 
Histones were previously considered to be an indication of apoptotic bodies 
Table 5: AUC and CI values for proteins 
Figure 14: ROC curves of selected candidates. 
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contamination in a vesicle isolation experiment (141). However, an increasing 
number of reports is showing that histones are frequently included in exosomes, 
where they can participate in the inclusion of DNA in the vesicular cargo, and some 
members of this family have been already included in panels of putative biomarkers 
(142-144). In addition, in our experimental setting we did not find correlations 
between H4 and other nuclear proteins, event that could point to a possible 
contamination due to large apoptotic bodies. For these reasons, histone H4 was 
included among the candidate biomarkers, though its canonical nuclear localization 
should be taken in consideration in the future validation experiments for this 
protein, as sources other than exosomes can interfere with its abundance. Another 
well performing candidate was the carbonic anhydrase II (CAH2). CAH2 is an enzyme 
that increases the speed of the reversible reaction that convert carbon dioxide and 
water to carbonic acid, that becomes bicarbonate ion in water with a loss of a 
proton. This enzyme is expressed along the nephron and interacts with a large 
number of transporters and ion exchangers: it has been shown that can stimulate 
the epithelial sodium-proton exchanger NHE3 in the proximal tubule, increases the 
activity of the electrogenic Na+/HCO3- cotransporter NBCe1, and regulates the 
activity of Pendrin (145-148). CAH2 is able also to physically interact with the 
cytosolic C-terminal of AQP1, stimulating water reabsorption. In CAH2-deficient 
mice it has been observed that AQP1 expression was increased while the levels of 
AQP2 and NKCC2 remained equal to wt (149). Although AQP1 is more abundant in 
BAH patients that have also significantly less CAH2 compared to APA and EH 
patients, we could not find a correlation and we cannot support the view of a direct 
regulation of AQP1 by CAH2. However, given the amount of interactions involving 
CAH2 and that AQP1 and 2 were statistically different even between APA and BAH, 
we can hypothesize that the two subtypes of PA may be different in their water 
reabsorption pathways mechanisms. 
Network analysis was carried out to detect functional protein associations. GO 
analysis for biological process identified 14 proteins involved in transport (vesicle-
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mediated transport, renal water transport, bicarbonate) (Figure 15). Proteins 
involved in water transport and vesicle-mediated transport were up-regulated in 
BAH patients while structural proteins (ACT1, MSN) were up-regulated in APA. 
Although STRING identified several protein-protein interactions, no relevant nodes 
were found, since interacting proteins were differentially regulated between the 
two experimental groups. 
In previous studies,  we demonstrated striking metabolic differences in urine 
samples of the two PA subtypes, and in our UEV proteomic study we detected 
differences in water reabsorption proteins and key regulators of acid-base 
equilibrium and ion transporters (77). Our exploratory study has pioneered the 
possibility to exploit these differences in UEV proteins for improving in, a non-
invasive way, the identification and characterization of PA subjects. However, some 
inherent limitations need to be taken into consideration. The main limitation is the 
limited number of patients included in our analysis. This limitation required the use 
of more stringent criteria to short-list our biomarker candidates, although is still 
possible that the separation performances have been overestimated due to 
overfitting. To confirm our findings, future studies should enroll a larger cohort of 
Figure 15: String analysis of protein differentially regulated between APA and BAH patients. 
Text mining interactions were excluded. Function of these protein is color-coded: 
red=transport; yellow=renal water transport; green= vesicle-mediated transport; blue= 
bicarbonate transport. 
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patients for the verification step, that would be conducted in parallel with different 
analysis or detection protocols (e.g. MRM, Elisa). Due to the sample size limitations, 
we also limited the stratification of patients and did not explore the possibility of 
identifying sex-specific biomarker candidates or testing multiple candidates in a 
panel to increase specificity. Both possibilities will however become viable in a larger 
sample size study. Once validated, UEV biomarkers able to discriminate between PA 
and EH could be used in clinic to help in the diagnostic workflow of primary 
aldosteronism, limiting the use of confirmatory test that can give rise to 
complications for patients. Biomarker able to characterize the PA subtype may 
improve the current diagnostic work-up providing an alternative to AVS and allowing 
a time-effective choice of the appropriate treatment. 
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5. Metabolomics 
We have performed serum metabolomics in PA and EH patients adopting a semi-
targeted approach MS strategy. Table 6 shows the biochemical and hormonal 
features of the patients in this study. As expected, significant differences are 
detected only for renin, aldosterone, ARR and serum potassium. 
Table 6: the biochemical and hormonal features of the patients in metabolomics study. 
Values are reported as mean ± SD. 
 
PA patients – 17  
(13 APA, 4 BAH) 
EH patients  - 37  
(27 low-ARR, 10 hi-ARR) 
pval 
Gender (m/f) 23/12 13/6 NS 
Age (ys) 48.56 ± 2.5 44.32 ± 2.26 NS 
BMI 27.18 ± 1 28.37 ± 0.83 NS 
Renin (pg mL-1) 4.178 ± 0.93 11.24 ± 1.43 <0.01 
Aldosterone (pg mL-
1)  
367.6 ± 48.25 158.5 ± 9.49 <0.01 
ARR 123.2 ± 34.13 33.25 ± 6.9 <0.05 
Serum K (mmol l-1)  3.45 ± 0.16 3.86 ±0.05 <0.05 
Creatinine (mg dl-1)  0.92 ± 0.08 0.87 ± 0.03 NS 
Glucose (mmol l-1)  4.89 ± 0.12 5.18 ±0.23 NS 
Cholesterol (mg dl-1) 202.9 ± 9.6 201.2± 7.53 NS 
Triglycerides (mg dl-
1) 
114.1 ± 15.85 100.8 ± 7.77 NS 
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5.1 Diagnosis and subgroups comparison 
We have analyzed 56 serum samples through a UHPLC-MS semi targeted approach, 
obtaining the relative quantitation of 164 metabolites. We started our analysis by 
comparing the different metabolites in all the experimental subgroups 
(characterized by a different diagnosis) that are involved in the diagnosis work-up of 
PA. In this setting, we included the group of hypertensive patients who resulted 
positive in the ARR screening (labeled as HI ARR), but negative to the IV-SLT, to have 
an insight on the metabolic status of hypertensive patients with a suppressible high 
level of aldosterone. We identified 19 metabolites significantly different within the 
groups of patients (ANOVA, adj. p<0.05). These metabolites were related to energy, 
b 
Figure 16: (a) PLS-DA analysis clustering. (b) Clustering analysis of best 25 metabolites 
obtained with ANOVA analysis. PLS-DA VIP score and clustering analysis have identified the 
same classes of metabolites. (c) Random forest analysis confirmed the group clustering and 
the clear separation between low-ARR and hi-ARR EH patients. 
a 
c 
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nucleotides metabolism, fatty acid metabolism and lipid mediators of inflammation 
(Figure 16). 
PLS-DA was conducted to identify the metabolite with the highest contribution to 
group separation. We found specific metabolic signatures for PA subtypes and, 
interestingly, we found that there was a clear separation between EH patients who 
result positive for ARR screening (hi-ARR) compared to patients that are tested 
negative. Results obtained with PLS-DA were validated by random forest analysis 
and clustering analysis, both confirming the separation of hi- and low-ARR clusters 
and the metabolic heterogeneity in APA and BAH groups.  
5.2 PA and EH comparison 
We then analyzed serum metabolome of the two main groups (PA and EH) including 
hi-ARR patients, to identify metabolic changes reflecting a constant and non-
suppressible high level of plasma aldosterone (Figure 17).  
Figure 17: (a) Volcano-plot showing metabolites with FC cutoff set at 1.5 and p<0.05. (b) 
Heatmap showing significant metabolites. APA subgroup was characterized by a high level 
of heterogeneity in energy-related metabolism. (c) Box and dotplots of some of the most 
significant hits and their relative ROC curve. 
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We found that purine metabolism was altered, with a decrease in adenosine and 
hypoxanthine plasma concentration for PA patients, that had also an increased 
plasmatic level of urate. Altered purine metabolism was also observed in our 
previous analysis on urine metabolome of PA and EH patients (77).  
Several reports have described associations between serum uric acid and 
hypertension or cardiovascular disease. Hyperuricemia has been found to be 
predictive of the development of hypertension and it has been reported a strong 
correlation with blood pressure in the majority of adolescents with EH of recent 
onset (150). In a rat model, mild hyperuricemia was induced by inhibiting uricase, 
resulting in hypertension that recapitulates the hemodynamic and histologic 
features observed in clinic and activation of RAAS, showing another link between 
uric acid and hypertension (151). Despite its physiological role as an antioxidant, 
high level of uric acid in serum have been independently correlated with 
cardiovascular events and it has been shown that this metabolite can perturbate 
blood pressure regulation and induce endothelial tissue damage through different 
mechanisms, including altered NO production and promotion of inflammation (150, 
152-155). Multiple cross-sectional studies and meta-analysis have reported that PA 
patients are exposed to a higher risk of cardiovascular events compared to 
hypertensive patients and, in this view, urate could be a promising marker for the 
evaluation of incidence of such effects (29, 30). Another interesting finding of this 
analysis is that adenosine is significantly lower in PA patients. Adenosine binds 
specific receptors (A2A) on vascular smooth muscle cells and induces muscle 
relaxation and vasodilation (156). In addition, it exerts many other activities that are 
protective on the blood pressure and endothelium homeostasis, including the 
modulation of cardiac remodeling after ischemia-reperfusion and the regulation of 
inflammatory response (157, 158). Consistently with our observations, van den Berg 
and colleagues have shown that adenosine plasma concentration is lower in PA 
patients and hypothesized that this can contribute to their higher susceptibility to 
cardiovascular events (159).  
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Energy metabolic pathways were also found to be different between PA and EH 
patients, showing an increased level of glycolysis intermediates as glycerol-3-
phosphate and pyruvate for PA patients, levels that were higher in the APA 
subgroup. Notably, PA patients were characterized also by a higher level of alpha-
ketoglutarate and glutamine, while the level of glutamate and oxoproline resulted to 
be lower. This may be indicative of a different regulation of glutamate shunting in 
the TCA, with possible downstream effects on the homeostasis of glutathione. No 
differences between PA and EH patients were found in arginine or citrulline 
metabolism, key metabolites in the NO pathway. 
Differences in metabolism of fatty acids were mainly found in the class of 
polyunsaturated fatty acids, including arachidonic, icosatrienoic and 
docosapentaenoic acids, found to be higher in EH patients. Differences were also 
detected in acyl-carnitines profile, where we detected an increased level of short 
chain carnitines (acyl-C4) for PA and hi-ARR patients, while medium and long chain 
carnitines were higher in low ARR patients. 
Sex-dependent differences were detected in the distribution of several long-chain 
fatty acids, proline, branched-chain amino acids, intermediates of tryptophan 
metabolism and prostaglandin E1, supporting the previous observations on sex-
specific differences in metabolic profiles.  
Our results indicate that PA and EH patients have specific metabolic signatures and 
that a non-suppressible high plasma level of aldosterone can have impact on purine 
and fatty acids metabolism. Interestingly, several metabolites of PA signature have 
been correlated with higher incidence of cardiovascular effects and, as a future 
perspective, these metabolites and the pathways involved should be investigated to 
identify promising therapeutic targets or markers that can provide prognostic 
information in clinical practice.  
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In our study we also found striking differences in the clustering of metabolic profile 
of hi-ARR and low-ARR hypertensive patients (Figure 16b). Patients positive for the 
ARR screening but negative for the confirmatory test are considered to be not 
affected by PA and treated as essential hypertensive patients (28). Our data 
indicates that EH patients who result positive for ARR screening have a different 
acyl-carnitines, eicosanoids and prostaglandin profiles when compare to ARR 
negative EH patients (Figure 18). Kisaka and colleagues used ARR screening to 
classify EH patients and investigated differences in cardiovascular risk in these two 
subpopulations, finding that high ARR can be an independent predictive marker of 
CV events (160). On the basis of this observation, we speculate that these metabolic 
a 
c 
Figure 18: (a) Heatmap of the metabolic comparison of low-ARR and hi-ARR EH patients and 
(b) volcano-plot showing metabolites with FC cutoff set at 1.5 and p<0.05. Both 
representations show a clear difference in acyl-carnitines profile and oxylipids. (c) Box and 
dotplots of some of the most significant hits. 
R
e
la
ti
v
e
 q
u
a
n
ti
ty
 (
A
U
) 
Prostaglandin Acyl C4 Acyl C12 
b 
60 
 
differences may have clinical and therapeutic implications and should be 
investigated further. Should the clinical relevance of these difference be confirmed, 
it could be advisable to routinely perform ARR screening also to assess the status of 
the RAAS in hypertensive patients, to specifically address their increased risk in 
developing adverse cardiovascular effects. 
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5.3 APA and BAH comparison 
PA subtyping is essential to determine the best therapeutic strategy for the 
treatment of the disease. In our previous study on urine metabolomics, we have 
found a strong metabolic discrimination between BAH and APA. We have 
investigated differences in serum metabolites of these two subtypes, as they are 
representative of the majority of PA cases.  
  
  
    
  
   
 
   
  
   
 
                  
  
  
  
   
   
 
   
    
    
    
 
 
 
 
 
 
  
  
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
   
   
Figure 19: (a) PLS-DA clustering of APA (in red) and BAH (green) samples. (b) Heatmap of 
the top-25 metabolites identified with t-test analysis. VIP score and clustering analysis 
concordantly identified the same metabolic pathways as differentially regulated between 
the two groups of PA patients. (c) Volcano plot, statistically significant metabolites in t-
test are highlighted. 
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PLS-DA analysis identified differences in metabolites mainly involved in energy and 
purine metabolism and sulfur-containing metabolites. Data were confirmed through 
clustering analysis (Figure 19). Top 25 metabolites resulting from PLS-DA analysis are 
included in table 7.  
APA patients were characterized to have a higher level of glycolysis and TCA cycle 
intermediates. In agreement to what our laboratory has previously found in the 
urine metabolomics experiment, we have also found significant differences in purine 
Table 7: contributors to PLS-DA separation. Not all metabolites reached statistical 
significance in t-test comparison. 
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metabolism intermediates (although no differences were detected for uric acid 
levels) and sulfur-containing metabolites.  
Dysregulation in carbohydrate metabolism, lipid profiles and circulating free fatty 
acids have been linked with hypertension (74). Altered purine metabolism has been 
shown strictly related with hypertension in different settings, although the focus of 
the majority of the studies was the end product uric acid (161, 162). Adenosine, a 
vasodilation effector involved in the “basal” arterial tone decreasing the overall 
vascular resistances, was altered in PA vs EH. Evidence in favor of a blunted 
vasodilation in response to acetylcholine in PA as compared with EH patients (in 
spite of similar BP values) is already reported in literature (163). It may be 
interesting to further investigate this aspect, that could be specifically ascribed to 
the mineralocorticoid activity on muscle vessels rather than the BP values. 
APA and BAH are both characterized by a hypertension caused by non-suppressible 
aldosterone secretion and their clinical distinction is paramount for identifying the 
appropriate therapeutic strategy. Our metabolomics analysis has shown that the 
two diagnosis subgroups are also characterized by a distinct metabolic signature in 
pathways related to hypertension, and those differences were detected in two 
different matrixes (serum and urine). This suggests that different causes of primary 
aldosteronism may impact differently the metabolic pathways related to 
hypertension. Little is known about the pathophysiological differences between APA 
and BAH subtypes, and genetic mechanisms of unilateral and bilateral primary 
aldosteronism are yet to be understood (14). The reason on why APA and BAH 
patients have a specific metabolic signature, despite being characterized by the 
qualitatively same expanded-volume aldosterone-dependent  mechanism, is still 
unknown, but we can speculate that the extent of metabolic and pathophysiologic 
alterations of adrenal tissue may dysregulate corticosteroids homeostasis and the 
downstream metabolic pathways (78, 164). 
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The different metabolic signature between APA and BAH patients opens the 
possibility of integrating metabolic profiling in the diagnostic work-up, to improve 
the PA characterization step.  
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5.4 APA patients and post-adrenalectomy follow up 
To identify metabolic changes associated with therapy in PA, we have followed up 7 
APA patients who underwent adrenalectomy 3 months, one year and two years 
after surgery.  
After surgery, systolic and diastolic blood pressure returned to normal ranges in all 
patients. Restoring of RAAS regulation was evident by a significant increase in renin 
plasma level and decrease of plasma aldosterone. Excretion of sodium in urine was 
found to be increased as well as potassium levels in the blood. In most cases, 
changes in biochemical and hormonal parameters were evident from the first follow 
up point (3 months after surgery) (Figure 20).  
Data were analyzed using the Multivariate Empirical Bayes Analysis of Variance 
(MEBA) for Time Series plugin in Metaboanalyst. Most of the metabolic changes 
were detected within the first 3 months after surgery and were maintained across 
the 2 years of follow up timespan.  
Figure 20: trends in biochemical and hormonal features of APA patients in the adrenalectomy 
follow-up. 
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We have measured an increase in free levels of the amino acids asparagine and 
glutamine and a correspondent decrease in aspartic and glutamic acids (figure 21a). 
Sulfur-containing compounds (methionine, homocysteine, taurine) were also found 
to be increased, suggesting a different regulation in sulfur exchange and a higher 
availability of compounds with ROS scavenging capabilities. Glutamine plays an 
important role in nitrogen exchange reactions and it has been reported to exert 
protective effects on cardiovascular physiology through different mechanisms 
including fueling NO generation, reducing blood glucose level and contributing in the 
maintenance of endothelial cells homeostasis (165). Key metabolites in NO pathway 
Figure 21: (a) overview on the regulation of some amino acids and related products. (b) key 
metabolites in NO synthesis pathway 
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(figure 21b) were found to be differentially regulated after adrenalectomy. Citrulline 
and ornithine were found to be increased 3 months after surgery; and higher serum 
level of these metabolites were maintained throughout the follow up. Conversely, 
arginine was not found to be significantly changed.  
Purine metabolism was found to be heavily influenced by aldosterone-producing 
adenoma removal (Figure 22). Specifically, adenosine, AMP and guanosine were 
decreased over the course of follow up, with adenosine level dramatically reduced 
within 3 months after surgery.  
Despite alterations to purine metabolites, we have not detected significant 
variations in urate levels. In the previous analysis, we have found that adenosine is 
lower in PA patients when compared to EH patients. A possible explanation for the 
drop in adenosine within the first 3 months after adrenalectomy is that circulating 
Figure 22: Overview of purine metabolism.  
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adenosine is tightly regulated by blood pressure, and with its normalization, the 
need for its vasodilation function is reduced altogether. 
Figure 23: Boxplot of lipids involved in inflammation signaling. Diagram adapded from Serhan et 
al. 2014 
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Future quantitative metabolomics study could provide more information about 
adenosine role in hypertension by investigating variations in serum adenosine 
concentration in a cohort of hypertensive patients (PA and EH) compared to 
normotensive subjects in basal conditions or exposed to volume changes.  
Lipidic mediators of inflammations class of compounds was found to be significantly 
changed after adrenalectomy (Figure 23). With the exception of prostaglandin A2, 
the other inflammatory lipids we have detected and measured are generally 
described by a decrease within the first 3 months after surgery. This was evident for 
pro-inflammatory lipids (prostaglandins, leukotrienes) but also for lipid associated 
with resolution of inflammation (resolvin D1 and 2). Arachidonic acid, precursor in 
the synthesis of prostaglandins, was found to be significantly decreased two years 
after surgery, while no significant changes were detected for eicosapentaenoic acid 
and docosahexaenoic acid (precursors of resolvins). Observations in human studies 
and animal models have established the existence of a link between hypertension 
and inflammation, even though cause-effect relation between the two factors is still 
a matter of debate (166). Several studies have reported that aldosterone can 
promote inflammation through various mechanisms including the stimulation of the 
expression of ICAM-1, MCP-1 and COX-2, responsible of the synthesis of 
prostaglandins. These effects are reduced in eplerenone treatments, suggesting that 
they are largely dependent on MR signaling (34-36, 167-169). Our data suggest that 
APA patients are characterized by a degree of basal (and persistent) activation of 
pro-inflammatory signals that is counterbalanced by pro-resolutions mediators. 
Adenosine, guanosine and lipid mediators of inflammation were found similarly 
reduced after 3 months after surgery, and their level was maintained similar up to 2 
years after surgery. One patient out of 7 was an exception to this trend (outlier 
evidenced in boxplots) and level reduction for these metabolites was reached only 2 
years after the adrenalectomy. Biochemical and hormonal parameters of this patient 
including plasma aldosterone, renin, systolic BP, diastolic BP were no different from 
those of the other patients (Figure 20). 
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In our follow-up studies we have indications that APA patients are characterized by 
alterations of vasodilating metabolites and an inflammatory burden that is resolved 
after surgery. With the exception of prostaglandin E2 (higher in hi-ARR hypertensive 
patients), we could not find differences in inflammatory mediators between PA and 
EH or APA and BAH, suggesting that this inflammatory burden is common in all the 
hypertensive conditions.  As a limitation of the study, a cohort of normotensive 
subjects was not included to confirm the hypothesis that inflammatory mediators 
characterize the hypertensive status. 
Two hypotheses can be formulated to explain the decrease (or “normalization”) of 
these systems: the first one is that removal of aldosterone-producing adenoma 
lowers the plasma level of aldosterone and the downstream cascade of pro-
inflammatory events that depend on MR signaling. The second one is that 
hypertension itself promotes and sustains inflammation, and the normalization of 
the blood pressure itself is sufficient to damp lipids pro-inflammatory mediation. In 
some cases, PA patients refuse to undergo surgery and they are successfully treated 
with MR antagonists. A prospective metabolomics study on this specific cohort of 
patients could help in understanding the contributions to inflammation in PA, as 
their plasma aldosterone level is still above the normal ranges but MR signaling is 
inhibited. One of the patients in our follow-up study was characterized by a slower 
reduction in adenosine or inflammation mediators, despite a rapid normalization of 
biochemical and hormonal parameters, suggesting that factors other than blood 
pressure, aldosterone, renin and serum potassium could contribute to reduction of 
inflammation and, possibly, the restoring of endothelium homeostasis after surgery. 
Taken together, our data on APA follow up indicate that APA removal not only 
improves blood pressure and restores the RAAS functionality but also impacts 
considerably the level of inflammation mediators, purine metabolism and key 
compounds in NO pathway. 
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6. Conclusions 
Identification and classification of primary aldosteronism requires a complex 
diagnostic work-up for the clinical similarity of symptoms with essential 
hypertension. In the effort to identify molecules able to separate the two classes of 
patients and to get new insights into the molecular features of PA, our lab has 
approached the problem with multiple strategies. These strategies included the 
analysis of UEV content to find potential biomarkers and up-to-date proteomics and 
metabolomics MS-based approaches, proven to be valuable for clinical oriented 
research in different settings. 
First, we developed a protocol for the analysis of mRNA content in UEV. To address 
the technical problem of scarcity of mRNA in UEV, we added a pre-amplification step 
for stabilizing target detection, and we decided to use normalization on 
housekeeping genes not prone to introduce DNA contamination. Notably, a similar 
protocol was developed in parallel by Bazzell and colleagues, who addressed the 
problem of the scarcity of mRNA content by adding a pre-amplification step as well, 
but suggesting the use of not normalized delta-CT for measuring the transcript level 
(88). We specifically focused on the mRNA of the NCC, a nucleic acid contained in 
UEV. Previous data have suggested that urinary exosomes of PA patients are 
characterized by an increased level of NCC and pNCC proteins when compared to 
exosomes from EH patients (66). Our hypothesis was that differences in protein 
abundance could be reflected by the level of the corresponding ribonucleic 
transcript and we investigated if it was possible use of the urinary NCC mRNA as a 
more stable and reliable marker of PA than the corresponding protein. The results 
did not support the use of NCC mRNA as marker of PA or to separate APA and BAH 
subtype, and there were indications that NCC protein abundance and mRNA 
regulation follow separated dynamics. Nevertheless, a secondary aim was to 
understand how the NCC mRNA is regulated in response to salt infusion and therapy 
(MRA and adrenalectomy). Our findings indicate that NCC mRNA expression is 
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down-regulated in response to Na-driven volume and that is up-regulated as 
compensatory mechanisms in case of hypovolemia following drug or surgical 
treatment. In our proof-of-concept study we showed that our UEV analysis protocol 
can provide information on the status of the renal tubule and help in the 
characterization of disease that impact on nephron homeostasis. We also provided 
evidence that, in the frame of the normalization debate for UEV, the use of 
creatinine should be taken with caution. The introduction of pre-amplification step 
in our protocol increased the sensitivity of the qPCR assay, thus allowing to perform 
the analysis with a limited amount of sample. However, it has been observed that 
this step may introduce bias and lower the reliability of qPCR results (170). To 
address this limitation, we selected a small panel of genes and used primers with 
efficiency close to 100%. The recent technological developments of  droplet-based 
digital PCR platforms (ddPCR), coupled with new protocols for the detection of rare 
transcripts, could open the possibility of avoiding the pre-amplification step, thus 
improving further our protocol for UEV mRNA analysis in the near future (171).  
In the second part of our project, we analyzed the UEV content using an untargeted 
label-free MS approach for biomarker-discovery purpose. Our findings showed that 
groups of protein associated to UEV composition are different between PA and EH, 
suggesting that UEV of different composition are released in the urine in the two 
conditions, thus UEV themselves could be considered as prospect biomarkers. 
Moreover, proteins related to water reabsorption and ion homeostasis were found 
among the most significant hits (AQP1, AQP2 for PA vs EH and CAH2 for APA vs BAH) 
indicating a different physiological equilibrium in renal transport between groups of 
patients and identifying possible targetable pathways that can be investigated 
further. The use of state-of-the-art proteomic techniques allowed us to obtain a list 
of promising candidates that could help in the diagnosis and characterization of PA. 
The use of network analysis for the identification of protein-protein interactions can 
extend the information obtained on the single proteins and lead to the identification 
of dysregulated pathways or cellular process that can be of clinical interest. As an 
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immediate future perspective of this study, we plan to investigate the clinical 
relevance of our candidate biomarkers for the identification and subtyping of 
primary aldosteronism by enrolling a larger cohort of patients and performing a 
parallel two-protocols validation with MS MRM and ELISA (172).  
To perform this proteomics analysis, we attempted at first to repurpose and adapt 
the same EV isolation protocol we used for the mRNA analysis. Preliminary data 
obtained comparing three different isolation methods (e.g. precipitating reagent, 
ultracentrifugation, ultrafiltration) indicated that the chemical precipitating reagent 
was interfering with the peptide detection and the ultracentrifugation resulted to be 
the best isolation method for proteomics, in terms of number of identified peptides. 
For this reason, we adopted the ultracentrifugation protocol that, while requiring a 
higher volume of sample, was shown to be better compatible with the downstream 
MS analysis. We believe there is potential for integrating the proteomics data with 
the transcriptomics information obtainable from the UEV, however the impact that 
may derive from the use of different isolation techniques on this kind of analysis is 
to be assessed. 
In our study we characterized the dimension of our isolated UEV through TEM. Their 
dimensions were found compatible with those of exosomes, although the clear 
demonstration of an exosomal nature of the isolated UEV was not accomplished as 
it would have required techniques that were not available at our site. Nevertheless, 
we acknowledge that a better characterization of the isolated UEV may have helped 
to evaluate qualitative differences between the proteomics and transcriptomics 
experiments. Further developments of this study will include a quantification step 
through Nanoparticle Tracking Analysis (NTA) and a surface marker profiling step 
through flow cytometry, as per indication of the ISEV position paper (72).  
Lastly, our metabolomics investigation has provided a considerable amount of 
information on the metabolic status of PA patients in comparison to EH patients. We 
have found that lipid, energy and purine metabolism are differentially regulated 
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between the two groups and that key metabolites in those pathways have been 
already associated to the risk of developing cardiovascular events. We showed that 
metabolism is different among hypertensive patients that are separated by the ARR 
scoring system. Though ARR was specifically designed to detect PA cases at high 
sensitivity and is not optimized for the classification of EH patients, it is clear that 
the RAAS status has a considerable impact on several metabolic pathways. The 
previous observation made on hi-ARR patients and their higher propensity of 
developing cardiovascular events points out that there are potential clinical benefits 
in scoring EH patients for their RAAS functionality. ARR score itself is subject to 
improvements and more sensitive alternatives are being investigated, opening to 
the opportunity to understand if the stratification of EH patients for their RAAS 
status is feasible and if it can provide benefits for their management (173).  
Interestingly, in the last part of our metabolomics study we have shown that 
adrenalectomy has mid-term effects on purine metabolism (with possible 
implications on endothelium homeostasis) and it leads to a decrease in 
inflammation-related signaling. Though it is still unclear if these effects are mediated 
by MR signaling and/or are a secondary effect of the normalization of blood 
pressure, this result strengthens the concept that adrenalectomy is beneficial for 
APA patients, considering the reported associations between inflammation and 
cardiovascular disease. Most of the metabolic changes occur in the first 3 months 
after surgery and, in the same time window, we have found an increase in NCC 
transcript in UEV. It will be of interest to integrate the metabolomics data by 
investigating, from a transcriptomics and proteomics perspective, how the profile of 
ion channels and transporters changes in the DCT district after adrenalectomy or 
MRA treatment. 
Mutations in at least 5 genes have been observed to be associated with APA, 
suggesting different possible biochemical origins for this phenotype. Indeed, despite 
a rapid normalization of blood pressure and plasma potassium occurred in all APA 
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patients after the adrenalectomy, we have observed some differences in the 
associated metabolic changes. It is possible that the differences in the underlying 
causes of APA may be reflected in differences in clinically relevant features. To 
better characterize this subtype, one current developments of this study is the 
metabolomic analysis of pathological and non-pathological adrenal tissue from the 
same APA patients here described. Gene sequencing is also being carried out with 
the aim of understanding the role of the known mutations in the biochemical and 
metabolic features of APA. 
Several serum metabolites and protein markers associated to UEV seem to have a 
potential clinical relevance in the diagnosis and characterization of this disease and 
for monitoring its treatment. As a future perspective, we plan to enroll a larger 
cohort of hypertensive patients for the verification step to confirm the efficacy of 
these prospect biomarkers. However, for the subsequent validation step there are 
some key factors to take into consideration. First, it is important to consider that the 
PA diagnosis algorithm is still codified by guidelines that do not identify “gold 
standards” techniques or cut-offs for screening, confirmation and subtyping. Starting 
from the same population of hypertensive subjects, the differences in the available 
techniques, know-how, instruments and adopted cut-off values across referral 
centers will probably lead to differences in the identification and sub-classification 
of the PA population. As consequence, if the validation of these prospect markers is 
run separately in different settings, there may be discrepancies in the biomarker 
panel that is finally suggested to be adopted in clinic. Second, the selection of 
patients in this study was made by following stringent criteria, to limit the effects of 
possible confounding factors. It is known that the diagnosis of PA of recent onset or 
mild cases of PA is challenging and indeed we have observed that there are 
metabolic similarities between PA and hi-ARR hypertensive patients. We expect that 
the specificity of some biomarkers identified in a clearly distinguishable population 
of PA patients will likely decrease in a real-world application. To better understand 
which biomarkers have a solid possibility to be used in clinic, we believe it is strongly 
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advisable that validation and verification steps enroll a large-number heterogeneous 
population and that the validation step is carried out in a multi-center setting. 
Taken together, our data highlight the importance of adopting a multiple -omics 
strategy coupled with multivariate statistics in biomarker discovery and, in general, 
to approach complex diseases. The use of UEV as a sort of “liquid biopsy” is a 
valuable and non-invasive method for the understanding of the pathophysiological 
mechanisms involved in PA. In the light of our findings and proposed protocols, we 
also foresee an opportunity for future studies pursuing a multi-omics approach that 
is integrated by design. 
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